Financial Performance - The company reported other income of RMB 28.1 million, a decrease of 60.4% year-on-year [1] - Research and development expenses amounted to RMB 117 million, down 7.3% year-on-year [1] - The net loss for the period was approximately RMB 149 million, a reduction of 47.5% year-on-year [1] - Loss attributable to shareholders was about RMB 148 million, a decrease of 47.22% year-on-year [1] Strategic Developments - The company achieved a significant milestone by licensing out soralimixin (BRII-693), a new antibiotic for treating severe MDR/XDR Gram-negative bacterial infections [2] - In July 2025, the company announced a partnership with Health元集团 to grant rights for research, development, and commercialization of soralimixin (BRII-693) in Greater China [2] - This partnership allows the company to focus its internal resources on core HBV projects while advancing the regional development and commercialization of soralimixin (BRII-693) [2] - Clinical data generated during the development process may support the drug's development in other regions [2]
腾盛博药-B(02137)公布中期业绩 公司拥有人应占亏损约1.48亿元 同比减少47.22%